title: Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T).
abstract: Acellular pertussis vaccines provide protection against whooping cough with few adverse effects. Their introduction to routine immunisation programmes would be facilitated by their incorporation with other routinely administered vaccines. 262 infants were immunised with an acellular pertussis vaccine containing pertussis toxin and filamentous haemagglutinin, combined with diphtheria and tetanus toxoids. This vaccine was mixed with Haemophilus influenzae type b tetanus toxoid vaccine (PRP-T) so that infants received a single injection at age 2, 3 and 4 months. One month after the third dose the geometric mean titre of Hib IgG antibody was 0.48 microgram ml-1. Eighty-two percent of infants achieved a titre of 0.15 microgram ml-1, with only 27% achieving 1.0 microgram ml-1. This combination vaccine induced low Hib antibody responses when compared to other studies in which PRP-T was mixed with acellular or whole-cell pertussis vaccines. The combined vaccine did, however, appear to prime a subset of 35 infants for response to a fourth dose of PRP-T at 13 months of age, with a rise in GMT from 0.21 microgram ml-1 to 36.6 micrograms ml-1. These data have important implications for the introduction of combination acellular pertussis vaccines.
authors.affiliation: Sheffield Institute for Vaccine Studies, University Department of Paediatrics, Sheffield Children's Hospital, U.K.. f.bell@sheffield.ac.uk
authors.forename: F
authors.initials: F
authors.lastname: Bell
authors.forename: P
authors.initials: P
authors.lastname: Heath
authors.forename: F
authors.initials: F
authors.lastname: Shackley
authors.forename: J
authors.initials: J
authors.lastname: MacLennan
authors.forename: N
authors.initials: N
authors.lastname: Shearstone
authors.forename: L
authors.initials: L
authors.lastname: Diggle
authors.forename: H
authors.initials: H
authors.lastname: Griffiths
authors.forename: E R
authors.initials: ER
authors.lastname: Moxon
authors.forename: A
authors.initials: A
authors.lastname: Finn
mesh_terms: D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D005260:Female; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood / Q000276:immunology; D007223:Infant; D008297:Male; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; D007074:Immunoglobulin G; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate